JM Tyrrell1, M. Woodward2, RA. Howe3, TR. Walsh1

Slides:



Advertisements
Similar presentations
A 23 Variability in the Size of the Fluoroquinolone AUC/MIC for Antibacterial Effect in S.aureus: Impact for Clinical Breakpoints A. R. Noel, K.E. Bowker,
Advertisements

Game plan Lecture Antibiotics Antibiotic resistance Gene transfer Transformation Transduction Conjugation Lab Lab Exam Pre-lab Transformation.
Other PD Models linked to the basic PK Model Modeling Diffusion into Porous Spherical Objects: Endocardial Vegetations, and the Post-Antibiotic Effect.
The Search for Hypermutability: Determining Frequency of Mutation in Mycobacterium smegmatis mc2155 ___________ Susan Puckett Mentors: Dr. Digby Warner,
Plasmids Chromosome Plasmid Plasmid + Transposon Plasmid + integron Plasmid+transposon +intergron Chromosome Chromosome + transposon Chromosome + transposon.
CHOICE OF ANTIBIOTICS IN THE VIEW OF DEVELOPING ANTIBIOTIC RESISTANCE Dr. Jolanta Miciulevičienė Vilnius City Clinical Hospital National Public Health.
IAFP’s 11 th European Symposium on Food Safety Cardiff, Wales April 2015 IAFP’s 11 th European Symposium on Food Safety Cardiff, Wales April.
Severity assessment for lower respiratory tract infections: potential use and validity of CRB-65 in primary care N. Francis, J. Cals, C. Butler, K. Hood,
Vesicle-Mediated Transfer of Antibiotic Resistance Between Klebsiella pneumoniae and Serratia marcescens Ondraya Espenshade Department of Biological Sciences,
The Effects of Bdellovibrio bacteriovorus on the Toxicity of E. coli in Chick Embryos Phil DeGaetano Department of Biological Sciences, York College of.
Antimicrobial Resistance patterns among nosocomial gram negative bacilli by E-test and disc diffusion methods in Sina and Imam Hospital.
Hospital Acquired Pneumonia(HAP): is defined as a pneumonia which occurs after 48 hours of admission to hospital. Hospital Acquired Pneumonia(HAP): is.
Introduction Staphylococcus aureus is a pathogen that is common in our surrounding environment. It is “responsible for a wide range of human disease, including.
Development of a Real-Time PCR (RT-PCR) Assay for Carbapenemase Producing Bacteria including Enterobacteriaceae B. Mather, P. L. White, M. Wootton, R.
Diamantis P. Kofteridis, Christina Alexopoulou, Antonios Valachis, Sofia Maraki, Dimitra Dimopoulou Clinical Infectious Diseases 2010; 51(11):1238–1244.
Tigecycline use in serious nosocomial infections: a drug use evaluation Matteo Bassetti*, Laura Nicolini, Ernestina Repetto, Elda Righi, Valerio Del Bono,
Phage therapy for the treatment for urinary tract infection: Results of in-vitro screenings and in-vivo application using commercially available bacteriophage.
Antibiotic-resistant Bacteria
Characterization of B-lactam resistance mechanisms among UTI isolates collected from women attending primary care across Europe- RGNOSIS P th ECCMID.
Nitroxoline does not result in microbiological eradication in geriatric patients with lower urinary tract infection: a prospective cohort study C. Forstner1,2*,,
Evaluation of chemical immersion treatments to reduce microbial counts in fresh beef Ahmed Kassem1, Joseph Meade1, Kevina McGill1, James Gibbons1, James.
Etiology of bacteremia in children under 5 years in Southern Mali
Pereira S.1*, Pereira C.1, Silva Y.J.1, Costa L1 and Almeida A.1
Introduction to Antimicrobial Resistance
Antibiotic Resistance
Dr.Mowna Karthick M.D MICROBIOLOGY
P th ECCMID 25 – 28 April 2015 Copenhagen, Denmark
Antibiotics: From Discovery to Resistance
High Fecal Carriage of Antibiotic Resistant Enterobacteriaceae Strains among Food Handlers in the West Coast Region of The Gambia Bakary Sanneh1*, Olliemattou.
carbapenemase-positive Enterobacteriaceae
Background Goals Methods Conclusions Results
International Journal of Infectious Diseases
Professor Alan Johnson Department of HCAI & AMR
Antibiotics sensitivity of microorganism causing nosocomial infections
Conclusions & Future Directions
Correspondence: Bactericidal Activity of Fosfomycin against NDM-1 producing Enterobacteriaceae M. Albur, A. Noel, K. Bowker, A.
النمو والعد البكتيري Microbial growth النمو الجرثومي.
D-739/181 50th ICAAC Sept , 2010 Boston
Introduction: Results: Methodology: Discussion: Conclusion:
Prevalence of CTX-M-14 type in Welsh Hospitals
Thirty-day mortality of nosocomial systemic bacterial infections according to antibiotic susceptibility in an 800-bed teaching hospital in France  D.
D-735/178 50th ICAAC Sept , 2010 Boston
Table 1: Resistance profile
Antimicrobial Resistance: from Global to Local
Activity of imipenem against VIM-1 metallo-β-lactamase-producing Klebsiella pneumoniae in the murine thigh infection model  G.L. Daikos, A. Panagiotakopoulou,
P1257 Pharmacodynamics of Amikacin Inhale studied in an in vitro pharmacokinetic model of infection KE Bowker, AR Noel, SG Tomaselli, MLG Attwood, AP.
Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome.
Role of inoculum and mutant frequency on fosfomycin MIC discrepancies by agar dilution and broth microdilution methods in Enterobacteriaceae  M. Ballestero-Téllez,
C th Interscience Conference on Antimicrobial Agents and Chemotherapy October 25-28, Washington, DC Examining Temocillin Activity in Combination.
C th Interscience Conference on Antimicrobial Agents and Chemotherapy October 25-28, Washington, USA Emergence of VIM-2 Metallo--lactamase.
Antibiotic Resistance
Non-antibiotic strategies for sepsis
Cell-wall-inhibiting antibiotic combinations with activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli  R.A. Hickman, D. Hughes,
Klebsiella pneumoniae: development of a mixed population of carbapenem and tigecycline resistance during antimicrobial therapy in a kidney transplant.
How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach  D. Guillemot  Clinical Microbiology.
ANTIBIOTIC RESISTANCE
P. Moreillon, J.M. Entenza  Clinical Microbiology and Infection 
Alvaro San Millan  Trends in Microbiology 
New Delhi metallo-beta-lactamase (NDM-1): towards a new pandemia?
Combating the rising global threat of antimicrobial resistance with clay minerals: A study on two major hospital superbugs E. C. Myles1*, I. A. Centeleghe1**,
W. -L. Yu, M. -F. Lee, H. -J. Tang, M. -C. Chang, J
Antibiotic susceptibility testing
Klebsiella pneumoniae: development of a mixed population of carbapenem and tigecycline resistance during antimicrobial therapy in a kidney transplant.
Activity of cefepime and carbapenems in experimental pneumonia caused by porin- deficient Klebsiella pneumoniae producing FOX-5 β-lactamase  C. Pichardo,
B. subtilis GS67 Protects C
Micro-organisms, evolution and antibiotic resistance
Treatment of G. mellonella-infected larvae with norfloxacin or norfloxacin plus TPGS in combination with the wild type or ΔbcnA mutant. Treatment of G.
Fighting MDR G-Negative Infections
Rapid detection of antibiotic resistance by MALDI-TOF mass spectrometry using a novel direct-on-target microdroplet growth assay  E.A. Idelevich, K. Sparbier,
Outcomes of infections caused by carbapenemase-producing Klebsiella pneumoniae, according to treatment regimen. Outcomes of infections caused by carbapenemase-producing.
Presentation transcript:

JM Tyrrell1, M. Woodward2, RA. Howe3, TR. Walsh1 Costs on fitness and pathogenicity of Colisitin & Tigecycline resistance in Multi-drug Resistant (MDR) Klebsiella pneumoniae JM Tyrrell1, M. Woodward2, RA. Howe3, TR. Walsh1  1Department of Medical Microbiology & Infectious Diseases, Cardiff University, Heath Park, Cardiff, Wales, UK. 2Department of Food & Nutritional Studies, University of Reading,UK, RG6 6AP. 3Public Health Wales Microbiology Cardiff , University Hospital of Wales, Heath Park, Cardiff, Wales, UK. Introduction Since its discovery in 2009, the NDM-1 metallo-β-lactamase, carried upon conjugative plasmids by species of Enterobacteriaceae, has disseminated on a global scale. NDM-1 producers are often pan-resistant to front-line antibiotics including carbapenems, aminoglycosides and fluoroquinolones, compromising patient treatment and recovery. Colistin (C) & Tigecycline (T) are frequently the only viable treatment options for NDM-1-positive infections, but resistance to even these is now being reported. Understanding the process and consequences of resistance to C&T on these potential pathogens is thus of great importance. Methods Test Sample: A self optimised passaging method was used to separately increase the C&T MICs of 9 NDM-1-positive Klebsiella pneumoniae (KP). Reversion of C&T Resistance: Once the increased MICs were stabilised, cultures of the C resistant and T resistant ‘mutants’ were re-inoculated into neat broth for 14 days. Every other day cfu counts were carried out with selective pressures at 0, 2, 8, 32 and 128µg/ml with the appropriate microbial (C/T) to deduce the rate at which resistance was being maintained/lost within the bacterial population. Galleria mellonella assay: Galleria mellonella were used as a model of pathogenicity. Larvae were infected with a controlled inocula of each test isolate, administered through the rear-left pro-leg into the larval hemocoel. N=10 larvae were used for each infection challenge. All larvae were incubated at 37ºc. Survival rates scored every 24 hours, death accepted once the larvae no longer responded to touch. Results Figure 1-IR37: (A) % of population growing at 2, 8, 32 & 128µg/ml Colistin over 14 reverse passage events. (B) % population growing at 2 & 8µg/ml Tigecycline over 14 reverse passage events. (C) Survival curves of IR37 WT, CR & TR. A B C Figure 2-IR12: (A) % of population growing at 2, 8, 32 & 128µg/ml Colistin over 14 reverse passage events. (B) % population growing at 2 & 8µg/ml Tigecycline over 14 reverse passage events. (C) Survival curves of IR37 WT, CR & TR. A B C Conclusions The above figures are representative of the results seen for all 9 of our KP test sample. The rates and strategies with which our KP isolates develop resistance to C&T decidedly variable (Table 1). Evolving C&T resistance has a negative impact on the growth rate and virulent capabilities of our KP, as seen in Figures 1c & 2c. There is no correlation between the two factors however. Having reached higher MICs and shown lower rates of population reversion (Figure 1a & b, 2a &b), we may assume that the strategies used in our Colistin ‘mutants’ may be carry less ‘cost’ than the corresponding strategies used by Tigecycline ‘mutants’. K1 HR1 HR2 IR12 IR15 IR17 IR18 IR34 IR37 Colistin WT 0.5 0.25 1 2 CR 128 (13) >128 (21) >128 (16) >128 (24) 128 (4) 128 (11) >128 (10) Tige TR 16 (30) 32 (30) >128 (15) 16 (22) Table 1: Colistin & Tigecycline MICs (µg/ml) of Wild Type (WT) and passaged (CR & TR) KP isolates. Number of passaging events for each ‘mutant’ is shown in brackets Email: tyrrelljm@cardiff.ac.uk